



Kako je HRDsig pomogao promijeniti tok Amandinog liječenja

Ne propustite nijednu pacijenticu poput Amande,* koja bi mogla biti kandidatkinja za PARPi ako je njen tumor pozitivan na HRDsig, pan-tumorski biomarker dostupan kroz Foundation Medicine.¹

Početna dijagnoza: metastatski trostruko negativni karcinom dojke

Amanda je dijagnozu dobila prije 2 godine. Budući da su testovi na germinalne BRCA1/2 mutacije i PD-L1 bili negativni, smjernicama preporučena prva linija liječenja bila je hemoterapija.²

Sada se bolest vratila.

1

Može li CGP testiranje uz HRDsig proširiti Amandine mogućnosti liječenja u drugoj liniji?

Njen ljekar naručuje FoundationOne®CDx testiranje. Nalaz pokazuje somatsku alteraciju PALB2 u tumoru. Tumor je i HRDsig-pozitivan (HRDsig+),¹ što ljekaru ukazuje na moguće dodatne terapijske opcije za Amandu.¹

2


HRDsig je inovativni biomarker koji se otkriva algoritmom mašinskog učenja, razvijenim u Foundation Medicine za različite solidne tumore.

HRDsig prepoznaje genomske ožiljke koji ukazuju na deficit homologne rekombinacije, neovisno o mutacijskom statusu HRR gena.¹

Podaci iz kliničke prakse povezuju HRDsig+ s koristi od PARPi terapije kod karcinoma dojke, jajnika i prostate, NSCLC-a i solidnih tumora, te s koristi od hemoterapije na bazi platine kod karcinoma gušterače.^{1,3-5,7,8}

3

Amandin ljekar sada je može uključiti u kliničko ispitivanje

U važećim odobrenim informacijama o PARP inhibitorima alteracija PALB2 nije povezana s deficitom homologne rekombinacije (HRD), ali HRDsig+ ukazuje da je HRD vrlo vjerovatno prisutan. Ovaj nalaz čini je potencijalnom kandidatkinjom za klinička ispitivanja PARP inhibitora i novih terapija usmjerenih na HRD+ tumore.^{1,6}



Šta je HRDsig?

Foundation Medicine HRDsig algoritam uzima u obzir veliki broj obilježja koja karakteriziraju HRD.¹


Koja je klinička korist HRDsig-a?

HRDsig može otkriti HRD u tumorima bez alteracija BRCA1/2 ili drugih poznatih HRR gena. Može prepoznati i slučajeve u kojima je alteracija HRR gena prisutna, ali ne uzrokuje HRD, čime se smanjuje broj lažno pozitivnih nalaza.¹

Postoji li posebna procedura naručivanja HRDsig-a?

Ne. HRDsig se automatski navodi u nalazu za sve tipove tumora poslane na FoundationOne CDx testiranje, ako je uzorak tumora adekvatan. Nije potrebno dodatno tkivo niti posebna procedura naručivanja.

Novi biomarkeri, uključujući HRDsig, mogu proširiti krug pacijenata s metastatskim karcinomom dojke koji su kandidati za PARP inhibitore.³



Naručite FoundationOne CDx za svoje odrasle pacijente s uznapredovalim solidnim tumorima i potencijalno proširite njihove terapijske opcije na PARP inhibitore.

<https://www.rochefoundationmedicine.com/#/en/international/ordering-support>

CGP = comprehensive genomic profiling; HRD = homologous recombination deficiency; HRR = homologous recombination repair; PARPi = PARP inhibitors

*HRDsig is reported as a laboratory professional service which has not been reviewed or approved by the FDA.

1. Moore JA, Chen KT, Madison R, et al. Pan-cancer analysis of copy number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP ribose) polymerase inhibitor response. *JCO Precis Oncol*. Sep 2023;7:e2300093. doi:10.1200/po.23.00093. 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer. Version 5. 2024 — October 15, 2024. 3. Batalini F, Madison RW, Sokol ES, et al. Homologous recombination deficiency landscape of breast cancers and real-world effectiveness of poly ADP-ribose polymerase inhibitors in patients with somatic *BRCA1/2*, germline *PALB2*, or homologous recombination deficiency signature. *JCO Precis Oncol*. Sep 2023;7:e2300091. doi:10.1200/po.23.00091. 4. Richardson DL, Quintanilha JCF, Danziger N, et al. Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by *BRCA1/2* and a scar-based HRD signature in real-world practice. *Clin Cancer Res*. Oct 15 2024;30(20):4644-4653. doi:10.1158/1078-0432.Ccr-24-1225. 5. Chen KT, Madison R, Moore J, et al. A novel HRD signature is predictive of FOLFIRINOX benefit in metastatic pancreatic cancer. *Oncologist*. Aug 3 2023;28(8):691-698. doi:10.1093/oncolo/oyad178. 6. Data on File, Foundation Medicine, Inc., October 2024. Full list of clinical trials enrolling patients with HRD-positive advanced breast cancer available at clinicaltrials.gov. Accessed November 1, 2024. 7. Riess JW, et al. Poster presented at ESMO 2024. Abstract 4752. 8. Anbil S, et al. Poster presented at AACR Advances in Pancreatic Cancer Research. Abstract C006.

FoundationOne®CDx is a qualitative next-generation sequencing based *in vitro* diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit <https://www.foundationmedicine.qarad.eifu.online/foundationmedicine/en/foundationmedicine?keycode=286605475>.

Roche farmacevtska družba d.o.o.
Stegne 13g
1000 Ljubljana, Slovenia
slovenia.diagnostics@roche.com
<https://diagnostics.roche.com/>

Roche d.o.o.
Ulica grada Vukovara 269a
10000 Zagreb, Croatia
croatia.diagnostics@roche.com
<https://diagnostics.roche.com/>
For HCPs only